Cargando…

Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

BACKGROUND: Immune checkpoint inhibitors (ICPIs) are increasingly being used in the treatment of a variety of malignancies. The original studies that demonstrated the efficacy of ICPIs excluded patients actively being treated for autoimmune conditions, and there is only limited evidence that these t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frohne, Christopher C., Llano, Ernesto M., Perkovic, Ashley, Cohen, Russell D., Luke, Jason J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322234/ https://www.ncbi.nlm.nih.gov/pubmed/30612589 http://dx.doi.org/10.1186/s40425-018-0484-x

Ejemplares similares

Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients
por: Rossi, Ernesto, et al.
Publicado: (2023)

Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac Allograft
por: Goodman, Amy E., et al.
Publicado: (2021)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy
por: Carbone, Maria Luigia, et al.
Publicado: (2023)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment
por: Trommer-Nestler, Maike, et al.
Publicado: (2018)

90. Fecal Microbiota Transplantation in Metastatic Melanoma Patients Resistant to Anti-PD-1 Treatment
por: Youngster, Ilan, et al.
Publicado: (2019)

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
por: Flaus, A., et al.
Publicado: (2021)

Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma
por: Jaberg-Bentele, Nicoletta F., et al.
Publicado: (2017)

Anti–NMDAR encephalitis in a patient with Crohn disease receiving adalimumab
por: Noble, Geoffrey P., et al.
Publicado: (2018)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis
por: Xu, Jun, et al.
Publicado: (2021)

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients
por: Dronca, Roxana, et al.
Publicado: (2015)

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
por: Bowyer, S, et al.
Publicado: (2016)

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
por: Turiello, Roberta, et al.
Publicado: (2020)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
por: Amato, Carol M., et al.
Publicado: (2020)

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
por: Parakh, Sagun, et al.
Publicado: (2021)

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
por: Babačić, Haris, et al.
Publicado: (2020)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
por: Xu, Weiran, et al.
Publicado: (2022)

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
por: Diem, S, et al.
Publicado: (2016)

Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
por: Herbreteau, Guillaume, et al.
Publicado: (2018)

Comparing the associations between host and tumor factors with survival outcomes with anti‐PD‐1 immunotherapy in metastatic melanoma
por: Koczka, Kim, et al.
Publicado: (2022)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017)

Renal Cell Carcinoma in Fistulizing Crohn's Disease Patient Who Received Anti-TNF α Therapy
por: Albishi, Abdullah Mohammed, et al.
Publicado: (2021)

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
por: Gellrich, Frank Friedrich, et al.
Publicado: (2020)

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
por: Bowyer, Samantha, et al.
Publicado: (2017)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
por: Ascierto, Paolo A., et al.
Publicado: (2015)

Clinical Management of Pneumonitis in Patients Receiving Anti–PD-1/PD-L1 Therapy
por: Bala-Hampton, Justin E., et al.
Publicado: (2018)

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
por: Ikeda, Sadakatsu, et al.
Publicado: (2016)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_68tmj70qitemb82l46ta3usfak